Anti Tau Immunotherapies For Alzheimer'S Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Anti-tau immunotherapies represent a promising disease-modifying approach for Alzheimer's disease and other tauopathies. These monoclonal antibodies and active vaccination strategies target pathological tau protein aggregates, aiming to slow or halt disease progression by clearing toxic tau species from the brain.
Pathological tau forms neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau oligomers and fibrils. Anti-tau immunotherapies work through:
| Drug Name | Company | Target Epitope | Stage | Key Notes |
|---|---|---|---|---|
| Zagotenemab (BE19071) | Eli Lilly | p-tau ( conformational) | Phase 2 | Showed biomarker effects but missed primary endpoint in TRAILBLAZER-ALZ 2 |
| Semorinemab (RO7105705) | Genentech/Roche | p-tau (Ser396/404) | Phase 2 | CITADEL-ALTZ; mixed results |
| Bepranemab (UCB0107) | UCB | p-tau (Ser208) | Phase 2 | Studies in AD and PSP |
| JNJ-63742057 | Johnson & Johnson | p-tau (pT217) | Phase 1 | Shows promise in early AD |
| Tilavonemab (ABBV-8E12) | AbbVie | N-terminal tau | Phase 2 | Studied in PSP and AD |
| Gosuranemab (BIIB092) | Biogen | N-terminal tau (fragments) | Phase 2 | Studied in AD and TBI |
| Liraglutide | Novo Nordisk | GLP-1 receptor | Phase 3 | Also known as NNC0114-0006 |
| Vaccine | Company | Target | Stage | Notes |
|---|---|---|---|---|
| AADvac1 | Axon Neuroscience | p-tau (Thr181) | Phase 2 | Showed safety and immunological response |
| ACI-35 | AC Immune | p-tau (Ser396/404) | Phase 1b/2a | Liposome-based vaccine |
| Disease | Rationale | Status |
|---|---|---|
| Alzheimer's Disease | Tau pathology correlates with cognitive decline | Multiple trials in Phase 2/3 |
| Progressive Supranuclear Palsy | Primary tauopathy | Tilavonemab, Bepranemab studied |
| Corticobasal Degeneration | 4R tauopathy | Early-stage trials |
| Primary Tauopathies | Various | Several candidates in development |
The study of Anti Tau Immunotherapies For Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.